PLANO, Texas, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced participation in the upcoming Piper Sandler 35th Annual Healthcare Conference to be held in New York City from Nov. 28–30, 2023.
Joseph Dziedzic, President and Chief Executive Officer, is scheduled to present on Wednesday, Nov. 29, 2023, at 10:00 a.m. EST. The presentation will be accessible via a live webcast.
The link to the live webcast may also be accessed under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net. A replay of the webcast will be available on the company’s website for approximately three months.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$133.12 |
| Daily Change: | 0.96 0.73 |
| Daily Volume: | 146,911 |
| Market Cap: | US$4.460B |
October 24, 2024 September 23, 2024 August 22, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
